Short-term cost shock forces an earnings reset, while the long-term share-gain thesis remains unchanged

Overview

Medline Industries' second-quarter underlying EBITDA was better than expected, but tariffs, fuel and raw material inflation, the Tracy distribution center fire, quality remediation, and weakness in the retail business led the company to lower its 2026 EBITDA guidance. Morgan Stanley accordingly reduced its 2026 to 2028 earnings forecasts and lowered its price target to $48. Although near-term earnings are facing clear disruption, the report believes the company's vertical integration capabilities, barriers in the medical consumables industry, Prime Vendor signing momentum, and the potential to convert customers to Medline-branded products can continue to drive long-term share gains and compound growth, supporting the maintained Overweight rating.

Core views

In the short term, approximately $340M of incremental costs in the second half of 2026 will pressure margins, and about $170M of cost impact may extend into 2027. Reported second-quarter EBITDA was $1.06B, including a $243M net benefit from IEEPA tariff refunds, with underlying EBITDA of approximately $817M; this one-time benefit was not included in the updated full-year guidance. Positives include about $140M of relative benefit from improved tariff cost assumptions, faster-than-planned Prime Vendor signing progress, and an increase in organic growth guidance to 9%-10%. Over the long term, the company is expected to continue expanding market share through vertical integration, service resilience, competitive replacement among hospital customers, and brand penetration within accounts.

Analysis framework

The report normalizes second-quarter reported profit into underlying operating performance, breaking down the impacts of tariff refunds, ongoing tariff costs, the distribution center fire, Middle East inflation, retail weakness, and quality remediation item by item; it then adjusts EBITDA and revenue growth forecasts for 2026 to 2028 and applies 2027 adjusted EBITDA multiples for base, bull, and bear case valuations.

Methodology notes

• Financial forecastingMorgan Stanley ModelWare

  Standardized earnings forecasting framework

  Unless otherwise noted, the forecast metrics in the report are based on the Morgan Stanley ModelWare framework and distinguish between company actuals, Morgan Stanley forecasts, and Refinitiv consensus expectations.

• Valuation methodsAdjusted EBITDA multiple valuation

  Enterprise value to adjusted EBITDA multiple

  The base price target of $48 is based on approximately 20.8x 2027 adjusted EBITDA and references the valuation levels of diversified and vertically integrated medtech and tools companies.

• Scenario analysisBull, base, and bear cases

  Combined sensitivity of growth, margins, and valuation multiples

  The report provides three valuation levels of $59, $48, and $26, reflecting different assumptions for brand conversion, market share, organic growth, margins, and tariff pressure.

• Earnings quality analysisOne-time items and underlying EBITDA adjustments

  Excluding non-recurring items

  The report excludes the $243M net benefit from IEEPA tariff refunds from second-quarter reported EBITDA to assess underlying EBITDA of approximately $817M and analyzes whether each cost item is included in full-year guidance.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• MDLN.US

  Direct positive coverage, but with near-term earnings expectations reduced

  Strengths

  Vertically integrated model, barriers in the medical consumables industry, customer service and supply resilience, Prime Vendor signing pipeline, share gains in hospital systems, and Medline brand conversion potential.

  Weaknesses

  Near-term margins are vulnerable to external costs, operational incidents, quality remediation, and changes among retail customers, weakening earnings visibility after the listing.

  Comparison

  The base valuation references diversified and vertically integrated medtech and tools companies; in the bear case, valuation could approach McKesson, implying a reduced brand conversion advantage.

  Risks

  Slower Prime Vendor signings, Medline brand conversion falling short of expectations, further increases in tariffs and inflation, extended quality remediation, follow-on costs from the distribution center fire, weak medical utilization, and slower market share growth.

Key data

• 2026 adjusted EBITDA guidance$3.3B-$3.4BLowered by about $200M versus prior guidance and excludes the $243M net benefit from IEEPA tariff refunds in the second quarter.
• Morgan Stanley 2026 EBITDA forecast$3.35BPrior forecast was $3.55B.
• Morgan Stanley 2027 EBITDA forecast$3.59BPrior forecast was $3.86B; the valuation page in the report lists a more precise figure of $3.597B.
• Incremental cost pressure in the second half of 2026Approximately $340MMainly related to the fire, inflation, retail weakness, and quality remediation.
• Estimated cost impact extending into 2027Approximately $170MEstimated by annualizing the roughly 50% recurring portion of the incremental costs in the second half of 2026.
• Second-quarter reported EBITDA$1.06BIncludes a $243M net benefit from IEEPA tariff refunds; underlying EBITDA was approximately $817M.
• Year-to-date Prime Vendor signingsApproximately $650MAbout 65% of the roughly $1B annual target, with signing progress ahead of plan.
• 2026 organic growth guidance9%-10%Morgan Stanley forecasts 9.6%, versus a prior forecast of 8.9%.
• Price target$48.00Lowered from $52, based on approximately 20.8x 2027 adjusted EBITDA.
• Base reference share price$36.67As of the close on August 5, 2026.
• Bull and bear case valuations$59 / $26Corresponding to stronger or weaker assumptions for brand conversion, share gains, revenue growth, margins, and valuation multiples.

Impact & implications

This guidance cut weakens earnings visibility in the company's early period as a public company and may pressure near-term valuation multiples, but the approximately 16.5x 2027 forecast EBITDA trading level already reflects some concerns. If Prime Vendor signings ultimately convert into revenue and penetration of the Medline brand within customer accounts increases, revenue growth and margins could recover, supporting valuation repair; conversely, if recurring costs exceed expectations or customer utilization weakens, there remains further downside risk to 2027 earnings forecasts.

Risks

• The recurring portion of incremental costs in the second half of 2026 may be higher than current estimates, putting further pressure on 2027 EBITDA.
• The timing of new Prime Vendor signings is uneven, and conversion from signings to actual revenue and profit may be slower than expected.
• If the pace of Medline brand conversion within customer accounts slows, it will reduce room for improvement in revenue mix and margins.
• Additional tariffs and higher fuel, raw material, and finished goods costs may have a greater impact on margins.
• The Tracy distribution center fire may continue to generate cleanup, rerouting, air freight, leasing, labor inefficiency, and capital expenditure pressure.
• Quality remediation spending and delays in relaunching products may continue to drag on earnings.
• Retail customer losses and weakness in the non-acute care business may persist through year-end.
• Medical utilization in the second half may weaken due to demand slowdown reflected in customer feedback.
• Morgan Stanley has investment banking and other business relationships with Medline Industries, and investors should be aware of potential conflicts of interest.

What to watch

• Whether approximately $650M of year-to-date Prime Vendor signings can successfully reach the roughly $1B annual target and convert into revenue.
• Execution of the 2026 organic growth guidance of 9%-10% and whether hospital supply volumes are affected by a slowdown in utilization.
• The actual composition of the approximately $340M of incremental costs in the second half, and whether costs extending into 2027 are controlled at around $170M.
• Whether net tariff costs can remain near the approximately $350M assumption and continue to reflect about $140M of upside versus prior expectations.
• The recovery progress of the Tracy distribution center, the effectiveness of sales rerouting, and whether capital expenditures remain within the $500M-$600M guidance range.
• Progress of the global quality action plan and the pace of relaunching related products.
• Whether Medline brand conversion, product mix improvement, and market share gains can drive a recovery in 2027 EBITDA growth.
• Whether the 2027 EBITDA forecast of approximately $3.59B and the 20.8x valuation multiple are supportable.